name: Polycystic Kidney Disease
category: Mendelian
description: >
  Polycystic kidney disease (PKD) is a genetic disorder characterized by the
  development of multiple fluid-filled cysts in the kidneys. The autosomal dominant
  form (ADPKD) is one of the most common inherited kidney diseases, affecting
  approximately 1 in 500-1000 people. ADPKD is caused by mutations in PKD1 or PKD2
  genes and typically presents in adulthood with progressive renal enlargement,
  hypertension, and eventual kidney failure. Autosomal recessive PKD (ARPKD) is
  less common and typically presents in infancy or childhood.
disease_term:
  preferred_term: polycystic kidney disease
  term:
    id: MONDO:0020642
    label: polycystic kidney disease
parents:
  - Genetic Kidney Disease
  - Ciliopathy
has_subtypes:
  - name: Autosomal Dominant PKD (ADPKD)
    description: Most common form, caused by PKD1 or PKD2 mutations, typically presenting in adulthood.
  - name: Autosomal Recessive PKD (ARPKD)
    description: Less common form caused by PKHD1 mutations, presenting in infancy or childhood with more severe phenotype.
pathophysiology:
  - name: Vasopressin/cAMP-Driven Cyst Expansion
    description: >
      Elevated vasopressin signaling via V2 receptors increases cAMP in tubular
      epithelial cells, driving chloride and fluid secretion into cysts and promoting
      cyst wall growth. Blocking V2 signaling slows total kidney volume expansion.
    evidence:
      - reference: PMID:29105594
        supports: SUPPORT
        snippet: "the vasopressin V2-receptor antagonist tolvaptan slowed the growth in total kidney volume"
        explanation: Tolvaptanâ€™s effect on kidney volume underscores vasopressin/cAMP signaling as a key driver of cyst expansion.
    cell_types:
      - preferred_term: nephron tubule epithelial cell
        term:
          id: CL:1000494
          label: nephron tubule epithelial cell
    biological_processes:
      - preferred_term: cAMP/PKA signal transduction
        term:
          id: GO:0141156
          label: cAMP/PKA signal transduction
  - name: Epithelial Proliferation and Kidney Enlargement
    description: >
      Reduced polycystin-mediated restraint on epithelial proliferation leads to
      progressive cyst wall growth and parenchymal compression, increasing total
      kidney volume and reducing renal function.
    evidence:
      - reference: PMID:29105594
        supports: SUPPORT
        snippet: "slowed the growth in total kidney volume and the decline in the estimated glomerular filtration rate"
        explanation: Dampening kidney volume growth parallels slower GFR loss, linking cyst epithelial proliferation to functional decline.
    cell_types:
      - preferred_term: nephron tubule epithelial cell
        term:
          id: CL:1000494
          label: nephron tubule epithelial cell
    biological_processes:
      - preferred_term: regulation of cell proliferation
        term:
          id: GO:0042127
          label: regulation of cell proliferation
  - name: Ciliary Dysfunction
    description: >
      Primary cilia act as mechanosensors in renal tubular epithelial cells.
      Polycystin dysfunction impairs ciliary signaling, disrupting normal tubular
      architecture and promoting cyst formation through increased cAMP signaling.
    evidence:
      - reference: PMID:29105594
        supports: SUPPORT
        snippet: "the vasopressin V2-receptor antagonist tolvaptan slowed the growth in total kidney volume"
        explanation: Reduction of cyst growth via V2 receptor blockade underscores cAMP-mediated ciliary signaling as a driver of cystogenesis.
    cell_types:
      - preferred_term: nephron tubule epithelial cell
        term:
          id: CL:1000494
          label: nephron tubule epithelial cell
    biological_processes:
      - preferred_term: cilium organization
        term:
          id: GO:0044782
          label: cilium organization
      - preferred_term: cAMP/PKA signal transduction
        term:
          id: GO:0141156
          label: cAMP/PKA signal transduction
  - name: Fibrosis and Inflammation
    description: >
      Progressive cyst growth triggers interstitial inflammation and fibrosis.
      Activated myofibroblasts deposit extracellular matrix, contributing to
      nephron loss and declining kidney function.
    evidence:
      - reference: PMID:40126492
        supports: SUPPORT
        snippet: "ADPKD accounts for 5% to 10% of kidney failure in the US and Europe"
        explanation: High kidney failure burden reflects cumulative nephron loss from cyst-driven injury and interstitial fibrosis.
    cell_types:
      - preferred_term: macrophage
        term:
          id: CL:0000235
          label: macrophage
    biological_processes:
      - preferred_term: inflammatory response
        term:
          id: GO:0006954
          label: inflammatory response
phenotypes:
  - name: Multiple Renal Cysts
    category: Renal
    frequency: VERY_FREQUENT
    description: Multiple fluid-filled cysts in both kidneys, progressively enlarging over time.
    phenotype_term:
      preferred_term: Multiple renal cysts
      term:
        id: HP:0005562
        label: Multiple renal cysts
    evidence:
      - reference: PMID:29105594
        supports: SUPPORT
        snippet: "the vasopressin V2-receptor antagonist tolvaptan slowed the growth in total kidney volume"
        explanation: REPRISE trial confirms PKD as a cystic kidney disease defined by progressive kidney volume increase.
      - reference: PMID:40126492
        supports: SUPPORT
        snippet: "Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive development of kidney cysts"
        explanation: JAMA review describes ADPKD as a progressive cystic kidney disease.
  - name: Hypertension
    category: Cardiovascular
    frequency: VERY_FREQUENT
    description: High blood pressure, often preceding decline in renal function.
    phenotype_term:
      preferred_term: Hypertension
      term:
        id: HP:0000822
        label: Hypertension
    evidence:
      - reference: PMID:40126492
        supports: SUPPORT
        snippet: "Hypertension affects 70% to 80% of patients with ADPKD"
        explanation: "JAMA review confirms very high prevalence of hypertension in ADPKD patients."
      - reference: PMID:40126492
        supports: SUPPORT
        snippet: "Optimal management of ADPKD includes systolic blood pressure lower than 120 mm Hg for most patients"
        explanation: Tight blood pressure targets underscore hypertension as a central clinical issue in ADPKD.
      - reference: PMID:40371605
        supports: SUPPORT
        snippet: "Comorbidities include hypertension, flank pain, and bacterial infections."
        explanation: Proteomic study lists hypertension as a common comorbidity in ADPKD cohorts.
  - name: Chronic Kidney Disease
    category: Renal
    frequency: VERY_FREQUENT
    description: Progressive decline in kidney function, with approximately 50% reaching end-stage renal disease by age 60.
    phenotype_term:
      preferred_term: Chronic kidney disease
      term:
        id: HP:0012622
        label: Chronic kidney disease
    evidence:
      - reference: PMID:29105594
        supports: SUPPORT
        snippet: "The change from baseline in the estimated GFR was -2.34 ml per minute per 1.73 m2"
        explanation: Trial demonstrates progressive GFR decline in PKD patients.
      - reference: PMID:40126492
        supports: SUPPORT
        snippet: "Approximately 50% of individuals with ADPKD require kidney replacement therapy by 62 years of age"
        explanation: High rate of kidney replacement therapy highlights progression to advanced CKD in ADPKD.
  - name: Hepatic Cysts
    category: Hepatic
    frequency: FREQUENT
    description: Liver cysts are common extrarenal manifestation, more prevalent in women.
    phenotype_term:
      preferred_term: Hepatic cysts
      term:
        id: HP:0001407
        label: Hepatic cysts
    evidence:
      - reference: PMID:40126492
        supports: SUPPORT
        snippet: "More than 90% of patients older than 35 years have hepatic cysts"
        explanation: "JAMA review confirms hepatic cysts as a very common manifestation in ADPKD."
      - reference: PMID:40126492
        supports: SUPPORT
        snippet: "More than 90% of patients older than 35 years have hepatic cysts, which may cause abdominal discomfort and occasionally require medical or surgical intervention"
        explanation: Describes prevalence plus symptomatic burden and intervention needs from hepatic cysts in ADPKD.
  - name: Intracranial Aneurysm
    category: Vascular
    frequency: OCCASIONAL
    description: Cerebral berry aneurysms occur in 5-10% of ADPKD patients, with risk of rupture.
    phenotype_term:
      preferred_term: Cerebral berry aneurysm
      term:
        id: HP:0007029
        label: Cerebral berry aneurysm
    evidence:
      - reference: PMID:40126492
        supports: SUPPORT
        snippet: "approximately 9% to 14% develop intracranial aneurysms"
        explanation: "JAMA review confirms intracranial aneurysms occur in 9-14% of ADPKD patients."
  - name: Flank Pain
    category: Renal
    frequency: FREQUENT
    description: Chronic or acute pain due to cyst hemorrhage, infection, or mass effect.
    phenotype_term:
      preferred_term: Flank pain
      term:
        id: HP:0030157
        label: Flank pain
    evidence:
      - reference: PMID:40371605
        supports: SUPPORT
        snippet: "Comorbidities include hypertension, flank pain, and bacterial infections."
        explanation: Proteomic study notes flank pain as a common comorbidity in ADPKD patients.
biochemical:
  - name: Elevated Creatinine
    presence: Elevated
    context: Marker of declining renal function in advanced disease
    evidence:
      - reference: PMID:29105594
        supports: SUPPORT
        snippet: "The change from baseline in the estimated GFR was -2.34 ml per minute per 1.73 m2"
        explanation: Progressive GFR decline reflects rising creatinine as renal function deteriorates.
  - name: Decreased GFR
    presence: Decreased
    context: Progressive decline reflecting nephron loss
    evidence:
      - reference: PMID:29105594
        supports: SUPPORT
        snippet: "as compared with -3.61 ml per minute per 1.73 m2 (95% CI, -4.08 to -3.14) in the placebo group"
        explanation: Trial quantifies ongoing GFR loss in ADPKD absent disease-modifying therapy.
genetic:
  - name: PKD1 Mutations
    association: Causative
    notes: Accounts for approximately 85% of ADPKD cases; encodes polycystin-1; typically more severe phenotype with earlier onset of ESRD
    evidence:
      - reference: PMID:40126492
        supports: SUPPORT
        snippet: "ADPKD is typically diagnosed in individuals aged 27 to 42 years and is primarily caused by pathogenic variants in the PKD1 (78%) or PKD2 (15%) genes."
        explanation: JAMA review quantifies PKD1 as the predominant cause of ADPKD.
  - name: PKD2 Mutations
    association: Causative
    notes: Accounts for approximately 15% of ADPKD cases; encodes polycystin-2; milder phenotype with later onset of ESRD
    evidence:
      - reference: PMID:40126492
        supports: SUPPORT
        snippet: "ADPKD is typically diagnosed in individuals aged 27 to 42 years and is primarily caused by pathogenic variants in the PKD1 (78%) or PKD2 (15%) genes."
        explanation: JAMA review documents PKD2 as a minority but established cause of ADPKD.
  - name: PKHD1 Mutations
    association: Causative
    notes: Causes autosomal recessive PKD; encodes fibrocystin/polyductin
    evidence:
      - reference: PMID:41467628
        supports: SUPPORT
        snippet: "Autosomal recessive polycystic kidney disease (ARPKD) is a rare disorder mainly caused by mutations in the polycystic kidney and hepatic disease 1 (PKHD1) gene."
        explanation: Clin Nephrol study states PKHD1 mutations as the primary cause of ARPKD.
environmental:
  - name: Caffeine Consumption
    notes: May accelerate cyst growth through increased cAMP levels; patients often advised to limit intake
    evidence:
      - reference: PMID:20301424
        supports: SUPPORT
        snippet: "Agents/circumstances to avoid: ... high levels of caffeine"
        explanation: GeneReviews lists high caffeine intake as an avoidable factor in ADPKD management.
treatments:
  - name: Tolvaptan
    description: >
      Vasopressin V2 receptor antagonist that slows cyst growth and kidney
      enlargement in ADPKD. First disease-modifying therapy approved for ADPKD.
      Requires hepatic monitoring due to risk of elevated liver enzymes.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
    evidence:
      - reference: PMID:29105594
        supports: SUPPORT
        snippet: "Tolvaptan resulted in a slower decline than placebo in the estimated GFR over a 1-year period in patients with later-stage ADPKD."
        explanation: REPRISE trial demonstrated tolvaptan efficacy in slowing GFR decline in PKD patients.
  - name: Blood Pressure Control
    description: >
      Aggressive hypertension management with ACE inhibitors or ARBs to slow
      disease progression and reduce cardiovascular risk.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
    evidence:
      - reference: PMID:40126492
        supports: SUPPORT
        snippet: "First-line treatment includes blood pressure control, dietary and weight management, and adequate hydration."
        explanation: "JAMA review confirms blood pressure control as first-line treatment for ADPKD."
  - name: Renal Dialysis
    description: >
      Dialysis (hemodialysis or peritoneal dialysis) for end-stage renal disease.
      PKD is one of the leading causes of kidney failure requiring dialysis.
    treatment_term:
      preferred_term: renal dialysis
      term:
        id: MAXO:0000601
        label: renal dialysis
    evidence:
      - reference: PMID:40126492
        supports: SUPPORT
        snippet: "Approximately 50% of individuals with ADPKD require kidney replacement therapy by 62 years of age."
        explanation: "JAMA review confirms high rate of kidney replacement therapy (dialysis/transplant) in ADPKD."
  - name: Kidney Transplantation
    description: >
      Kidney transplantation is the preferred treatment for end-stage renal disease
      in PKD. Native nephrectomy may be required if kidneys are too large.
    treatment_term:
      preferred_term: organ transplantation
      term:
        id: MAXO:0010039
        label: organ transplantation
    evidence:
      - reference: PMID:40126492
        supports: SUPPORT
        snippet: "Approximately 50% of individuals with ADPKD require kidney replacement therapy by 62 years of age."
        explanation: "JAMA review confirms high rate of kidney replacement therapy (dialysis/transplant) in ADPKD."
differential_diagnoses:
  - name: Simple Renal Cysts (Age-Related)
    disease_term:
      preferred_term: simple renal cyst
      term:
        id: MONDO:0004840
        label: non-congenital cyst of kidney
    description: >
      Solitary or few benign cysts that enlarge slowly with age and lack family history
      or extrarenal cysts. ADPKD shows bilateral numerous cysts with progressive total
      kidney volume growth.
    distinguishing_features:
      - Typically solitary or few cysts without kidney enlargement
      - No hepatic cysts or family history of cystic disease
      - Stable kidney function and volume over time
    evidence:
      - reference: PMID:29105594
        supports: SUPPORT
        snippet: "the vasopressin V2-receptor antagonist tolvaptan slowed the growth in total kidney volume"
        explanation: Progressive total kidney volume growth distinguishes ADPKD from stable simple cysts.
  - name: Acquired Cystic Kidney Disease (ACKD)
    disease_term:
      preferred_term: acquired cystic kidney disease
      term:
        id: MONDO:0002473
        label: cystic kidney disease
    description: >
      Cystic change that develops in chronically dialyzed kidneys, usually in the
      setting of long-standing kidney failure. Kidneys are often small or normal size
      rather than massively enlarged as in ADPKD.
    distinguishing_features:
      - Occurs after years of dialysis or advanced CKD without family history
      - Kidneys remain small/normal sized rather than enlarged
      - Lacks extensive hepatic cysts common in ADPKD
    evidence:
      - reference: PMID:40126492
        supports: SUPPORT
        snippet: "Patients with MIC 1C to MIC 1E have larger kidneys because of more rapid growth (6%-10% per year)"
        explanation: Rapid kidney enlargement in ADPKD contrasts with small kidneys seen in ACKD.
  - name: Tuberous Sclerosis Complex (TSC)
    disease_term:
      preferred_term: tuberous sclerosis
      term:
        id: MONDO:0001734
        label: tuberous sclerosis
    description: >
      Genetic disorder with renal cysts and angiomyolipomas that can mimic ADPKD but
      accompanied by dermatologic and neurologic manifestations.
    distinguishing_features:
      - Renal angiomyolipomas and cortical tubers with seizures or developmental issues
      - Cutaneous findings (facial angiofibromas, hypomelanotic macules) absent in ADPKD
      - ADPKD frequently shows extensive hepatic cysts, which are uncommon in TSC
    evidence:
      - reference: PMID:40126492
        supports: SUPPORT
        snippet: "More than 90% of patients older than 35 years have hepatic cysts"
        explanation: High hepatic cyst burden supports ADPKD over TSC when liver cysts dominate.
datasets:
  - accession: geo:GSE7869
    title: Expression data from renal cysts of autosomal dominant polycystic kidney disease (ADPKD) patients
    description: Microarray profiling comparing ADPKD kidney cyst epithelium with non-cystic kidney tissue to identify dysregulated pathways in cyst growth.
    organism:
      preferred_term: human
      term:
        id: NCBITaxon:9606
        label: Homo sapiens
    data_type: MICROARRAY
    sample_types:
      - preferred_term: kidney epithelium
        tissue_term:
          preferred_term: kidney
          term:
            id: UBERON:0002113
            label: kidney
    conditions:
      - ADPKD cyst epithelium
      - non-cystic kidney tissue
    publication: PMID:19346236
    notes: >-
      Public ADPKD microarray dataset frequently used to study cystogenesis-related signaling changes.
    evidence:
      - reference: PMID:23524344
        supports: SUPPORT
        snippet: "Microarray data are available at GEO website (accession number: GSE7869)."
        explanation: Confirms the GEO accession for the ADPKD cyst epithelium microarray dataset.
      - reference: PMID:19346236
        supports: SUPPORT
        snippet: "To elucidate the molecular pathways that modulate renal cyst growth in ADPKD, we performed global gene profiling on cysts of different size (<1 ml, n = 5; 10-20 ml, n = 5; >50 ml, n = 3) and minimally cystic tissue (MCT, n = 5) from five PKD1 human polycystic kidneys using Affymetrix HG-U133 Plus 2.0 arrays."
        explanation: Describes the PKD1 cyst epithelium microarray experiment underlying GSE7869.

  - accession: gtex:GTEx_v8_Kidney_Cortex
    title: GTEx v8 kidney cortex bulk RNA-seq
    description: Bulk RNA-seq from healthy kidney cortex samples providing control transcriptomes for comparison to ADPKD cystic tissue.
    organism:
      preferred_term: human
      term:
        id: NCBITaxon:9606
        label: Homo sapiens
    data_type: BULK_RNA_SEQ
    sample_types:
      - preferred_term: kidney cortex
        tissue_term:
          preferred_term: kidney cortex
          term:
            id: UBERON:0001225
            label: kidney cortex
    publication: PMID:39815096
    notes: >-
      Healthy kidney reference transcriptomes useful as baseline controls for differential expression analyses in ADPKD studies.
    evidence:
      - reference: PMID:39815096
        supports: SUPPORT
        snippet: "The data will comprise whole-genome sequencing, extensive bulk, single-cell and spatial gene expression profiles, and chromatin accessibility data across tissues and development."
        explanation: Establishes dGTEx as a bulk expression resource providing control transcriptomes across tissues including kidney.
